POS1526 TREATMENT EFFECTS OF IXEKIZUMAB AND ADALIMUMAB AT THE INDIVIDUAL DIGIT LEVEL WITH NAIL AND DISTAL INTERPHALANGEAL JOINT INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS

Background The prevalence of nail disease in patients with psoriatic arthritis (PsA) ranges between 41% and 93% [1] . Psoriatic is intimately linked to adjacent distal interphalangeal joint (DIP) disease, it important ascertain whether DIP-nail complex behaves differently under different biological therapies. Objectives aim this analysis was comparatively assess the effect ixekizumab (IXE) adalimumab (ADA) at individual digit level improving PsA concomitant involvement. Methods This post hoc included from SPIRIT-H2H ( NCT03151551 ) treated either IXE or ADA who had baseline (NAPSI total score >0) DIP involvement least one simultaneous digit, tenderness, swelling both, for each hand. Proportions having a NAPSI >0 proportions (tenderness swelling) were evaluated Week 24; post-baseline assessments compared treatment arms using Fisher’s exact test. Results Of intent-to-treat population (N=566), 354 (swelling tenderness) 1 simultaneously (IXE, N=186 ADA, N=168). these patients, significantly fewer IXE- vs. ADA-treated > 0 24 (p<0.05 9/10 digits; Table 1) numerically across all 10 digits 4/10 1). Numerically tenderness 24. A similar pattern improvement seen out 52 (Table Conclusion In analysis, baseline, less involvement, those Reference [1]Ogdie A. Weiss P. Rheum Dis Clin North Am. 2016;41(4): 545–568 1. proportion (%) (A) (B) among (N=186) (N=168) baseline. *p<0.05, †p<0.1, ‡p<0.001 vs Exact test p-value. Left Hand Right Little Ring Middle Fore Thumb (%)Week Q4W Q2W 17.0 * 27.9 17.6 14.2 † 25.5 15.3 27.3 11.4 23.6 13.6 26.7 15.9 13.1 21.2 p-value* 0.0191 0.0276 0.0097 0.0079 0.0039 0.0062 0.0113 0.0169 0.0602 10.9 21.4 10.3 16.6 17.2 9.1 14.5 12.1 19.3 9.7 7.3 12.4 0.0128 0.1304 0.2400 0.0958 0.1547 0.0859 0.0641 0.0538 0.1770 0.3924 10.7 11.3 15.8 19.8 17.5 20.9 21.5 11.9 15.2 20.0 24.8 22.4 28.5 30.9 18.8 0.2590 0.0357 0.0319 0.1249 0.1115 0.1307 0.1312 0.0495 0.2168 0.0459 1.2 2.8 2.4 4.8 7.2 8.3 5.4 5.5 6.2 1.8 4.1 4.2 7.6 0.4228 0.3578 0.8322 1.0000 0.0273 0.3128 0.2305 0.0703 0.1521 Data are presented as (%). *Fisher’s Abbreviations: adalimumab; IXE, ixekizumab. Acknowledgements: NIL. Disclosure Interests Dennis McGonagle Speakers bureau: AbbVie, Eli Lilly Company, Incyte, Janssen, Regeneron, Sanofi-Genzyme, Consultant of: Alumis, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol-Myers-Squibb, Connect Biopharma, Dermavant, EPI Health, Evelo Biosciences, Leo, Maruho, Meiji Seika Pharma, Mindera Novartis, Pfizer, UCB Sun Union Ventyxbio, vTv CorEvitas/Corrona Psoriasis Registry, Arthur Kavanaugh UCB, Abbvie, BMS Grant/research support from: Iain McInnes BMS, Causeway Cabaletta, Gilead, Sanofi, Evelo, Compugen, AstraZeneca, Moonlake, Lars Erik Kristensen Galapagos, Janssen pharmaceutical, Zuellig pharma, Joseph F. Merola Celgene, Biogen, Leo Pharma. (ALL honoraria received), IDEC, Sanofi Novartis. All funds paid Brigham Women’s Hospital., Bruce Strober Lilly, Company Rebecca Bolce Shareholder Employee Jeffrey Lisse Jennifer Pustizzi Christophe Sapin Christopher T. Ritchlin BMS,UCB, Pfizer.